What is Leerink Partnrs’ Estimate for MDGL FY2028 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Investment analysts at Leerink Partnrs increased their FY2028 EPS estimates for shares of Madrigal Pharmaceuticals in a research report issued to clients and investors on Thursday, October 31st. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical company will post earnings per share of $38.76 for the year, up from their previous estimate of $38.44. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($27.27) per share.

Other research analysts have also recently issued research reports about the company. Oppenheimer dropped their price target on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. UBS Group boosted their target price on shares of Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a report on Friday. StockNews.com upgraded shares of Madrigal Pharmaceuticals to a “sell” rating in a research note on Saturday, October 12th. Evercore ISI dropped their price objective on shares of Madrigal Pharmaceuticals from $405.00 to $360.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Finally, Citigroup cut their price objective on shares of Madrigal Pharmaceuticals from $382.00 to $371.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $344.33.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $331.32 on Monday. The company has a quick ratio of 8.67, a current ratio of 8.72 and a debt-to-equity ratio of 0.14. The firm’s fifty day simple moving average is $228.91 and its 200 day simple moving average is $243.57. The stock has a market cap of $7.19 billion, a P/E ratio of -13.21 and a beta of -0.46. Madrigal Pharmaceuticals has a twelve month low of $133.99 and a twelve month high of $337.44.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.94) by $2.02. The company had revenue of $62.18 million during the quarter, compared to the consensus estimate of $34.60 million. During the same period last year, the firm posted ($5.34) EPS.

Insider Transactions at Madrigal Pharmaceuticals

In related news, CEO William John Sibold sold 6,363 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the completion of the sale, the chief executive officer now directly owns 55,887 shares in the company, valued at $13,626,927.21. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Avoro Capital Advisors LLC raised its stake in shares of Madrigal Pharmaceuticals by 5.7% in the second quarter. Avoro Capital Advisors LLC now owns 2,055,555 shares of the biopharmaceutical company’s stock worth $575,884,000 after purchasing an additional 111,111 shares during the last quarter. Paulson & CO. Inc. raised its position in Madrigal Pharmaceuticals by 4.2% during the 2nd quarter. Paulson & CO. Inc. now owns 1,850,000 shares of the biopharmaceutical company’s stock worth $518,296,000 after buying an additional 75,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Madrigal Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,668,806 shares of the biopharmaceutical company’s stock valued at $445,638,000 after acquiring an additional 94,064 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Madrigal Pharmaceuticals by 106.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 803,213 shares of the biopharmaceutical company’s stock valued at $214,491,000 after acquiring an additional 414,484 shares during the last quarter. Finally, Fiera Capital Corp acquired a new stake in shares of Madrigal Pharmaceuticals in the second quarter worth $32,335,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.